scispace - formally typeset
T

Tania C. Felizardo

Researcher at National Institutes of Health

Publications -  22
Citations -  6238

Tania C. Felizardo is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Immune system & T cell. The author has an hindex of 11, co-authored 21 publications receiving 5620 citations. Previous affiliations of Tania C. Felizardo include University Health Network & Ontario Institute for Cancer Research.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

The PDL1-PD1 axis converts human TH1 cells into regulatory T cells.

TL;DR: It is shown that an inhibitory protein called programmed death ligand 1 (PDL1) can regulate renegade immune cells by converting immune response–promoting T helper type 1 (TH1) cells to regulatory T (Treg) cells—agents that selectively suppress activation of the immune system.
Journal ArticleDOI

PD-1 regulates KLRG1+ group 2 innate lymphoid cells.

TL;DR: It is demonstrated here that PD-1 is an important negative regulator of KLRG1+ ILC-2 function in both mice and humans and is required for maintaining the number, and hence function, of K LRG1-2s.
Journal ArticleDOI

Bone Marrow‐Derived Mesenchymal Stromal Cells Harness Purinergenic Signaling to Tolerize Human Th1 Cells In Vivo

TL;DR: Investigating immune modulation by a clinical‐grade BMSC product in a model of human‐into‐mouse xenogeneic graft‐versus‐host disease mediated by human CD4+ Th1 cells found it effectively modulate experimental GVHD through a paracrine mechanism that promotes adenosine‐based immune suppression.